Compare TGE & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | CPHI |
|---|---|---|
| Founded | 2023 | N/A |
| Country | France | China |
| Employees | 166 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 41.3M |
| IPO Year | N/A | 2008 |
| Metric | TGE | CPHI |
|---|---|---|
| Price | $0.67 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 509.1K | ★ 3.9M |
| Earning Date | 09-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $0.38 |
| 52 Week High | $3.21 | $19.19 |
| Indicator | TGE | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 42.48 |
| Support Level | N/A | $0.53 |
| Resistance Level | $0.99 | $0.68 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 3.87 | 3.70 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.